TKPHF - Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

2025-01-13 05:55:13 ET

Summary

• Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025.
• Topline results from the phase 3 VERIFY study, using rusfertide for the treatment of patients with polycythemia vera, expected in Q1 of 2025.
• The global Polycythemia vera market size is expected to grow to $2.03 billion by 2032.
• The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027.

Protagonist Therapeutics ( PTGX ) is gearing up to report top-line results from its phase 3 VERIFY study using its subcutaneous injectable Hepcidin Mimetic rusfertide [PTG-300] for the treatment of patients with Polycythemia Vera [PV]. Such data is expected to be released at some point during this Q1 of 2025. Whether or not the data ends up being positive remains to be seen, but the good thing about this company is that another partnered drug from its pipeline has already achieved success in two phase 3 studies. In essence, the company announced that the primary endpoints for both late-stage ICONIC-LEAD and ICONIC-TOTAL, were met with statistical significance for the treatment of patients with moderate to severe plaque psoriasis. The drug used for these phase 3 trials was oral IL-23R antagonist JNJ-2113 [formerly PN-235]....

For further details see: